Long-term treatment with the second-generation nucleosideanalogue lamivudine (lam) efficiently inhibits HBV replication with frequent viral polymerase mutations.
二代拉米夫定的长期应用可以有效地抑制病毒多聚酶突变频繁的HBV发生复制。
2
Effective treatment options for individuals with chronic hepatitis B infection were limited until 1998 when lamivudine, the first nucleosideanalogue drug, was introduced.